71 related articles for article (PubMed ID: 10442192)
1. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Planting AS; Catimel G; de Mulder PH; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken JB
Ann Oncol; 1999 Jun; 10(6):693-700. PubMed ID: 10442192
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Randomised Comparative Study Between Weekly Cisplatin Versus Three Weekly Cisplatin with Radiotherapy in Unresectable Locally Advanced Head and Neck Cancer.
Panihar C; Rawat S; Singotia L; Raj A; Jain RK
Indian J Otolaryngol Head Neck Surg; 2022 Oct; 74(Suppl 2):2670-2675. PubMed ID: 36452529
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin.
Veldman A; van Oosbree A; Braun M; Gurumoorthy A; Spanos WC; Powell S
Cancer Invest; 2023 Dec; 41(10):807-815. PubMed ID: 37962276
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
6. Audiologic Follow-up in Patients With Head and Neck Cancer Treated With Cisplatin and Radiation.
Lee DS; Travis EY; Wong SK; Collopy C; McClannahan KS; Ortmann AJ; Rich JT; Pipkorn P; Puram SV; Jackson RS; Paniello RC; Adkins DR; Oppelt P; Thorstad WL; Wick CC; Zevallos JP; Mazul AL
Laryngoscope; 2023 Nov; 133(11):3161-3168. PubMed ID: 36995150
[TBL] [Abstract][Full Text] [Related]
7. Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.
Falco A; de Oliveira TB; Cacicedo J; Ospina AV; Ticona MÁ; Galindo H; Pereira MD; Aguilar-Ponce JL; Rueda-Domínguez A; Soria T; Taberna M; Iglesias L; Sowley T; Mesía R;
Cancer Manag Res; 2021; 13():6689-6703. PubMed ID: 34471383
[TBL] [Abstract][Full Text] [Related]
8. Use of amifostine in the treatment of recurrent solid tumours in children.
Sidi V; Arsos G; Papakonstantinou E; Hatzipantelis E; Fragandrea I; Gombakis N; Koliouskas E
Hippokratia; 2007 Jan; 11(1):25-9. PubMed ID: 19582173
[TBL] [Abstract][Full Text] [Related]
9. TLR4/Inflammasomes Cross-Talk and Pyroptosis Contribute to N-Acetyl Cysteine and Chlorogenic Acid Protection against Cisplatin-Induced Nephrotoxicity.
Badr AM; Al-Kharashi LA; Attia H; Alshehri S; Alajami HN; Ali RA; Mahran YF
Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986437
[TBL] [Abstract][Full Text] [Related]
10. Protective Effect of Natural Antioxidants on Reducing Cisplatin-Induced Nephrotoxicity.
Zhou J; Nie RC; Yin YX; Cai XX; Xie D; Cai MY
Dis Markers; 2022; 2022():1612348. PubMed ID: 36419843
[TBL] [Abstract][Full Text] [Related]
11. Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.
Chen CH; Huang CY; Lin HH; Wang MC; Chang CY; Cheng YF
JAMA Netw Open; 2021 Aug; 4(8):e2118895. PubMed ID: 34338793
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Freyer DR; Brock PR; Chang KW; Dupuis LL; Epelman S; Knight K; Mills D; Phillips R; Potter E; Risby D; Simpkin P; Sullivan M; Cabral S; Robinson PD; Sung L
Lancet Child Adolesc Health; 2020 Feb; 4(2):141-150. PubMed ID: 31866182
[TBL] [Abstract][Full Text] [Related]
13. Increase in Protective Effect of
Vu-Huynh KL; Le THV; Nguyen HT; Kim HM; Kang KS; Park JH; Nguyen MD
Molecules; 2019 Dec; 24(24):. PubMed ID: 31861213
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital.
Ezzi MS; Othieno-Abinya NA; Amayo E; Oyiro P; McLigeyo A; Yatich RB; Shoba B
J Glob Oncol; 2019 Sep; 5():1-6. PubMed ID: 31479343
[TBL] [Abstract][Full Text] [Related]
15. Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis.
Hamroun A; Lenain R; Bigna JJ; Speyer E; Bui L; Chamley P; Pottier N; Cauffiez C; Dewaeles E; Dhalluin X; Scherpereel A; Hazzan M; Maanaoui M; Glowacki F
Drugs; 2019 Sep; 79(14):1567-1582. PubMed ID: 31429065
[TBL] [Abstract][Full Text] [Related]
16. Protective Role of Epigallocatechin Gallate in a Rat Model of Cisplatin-Induced Cerebral Inflammation and Oxidative Damage: Impact of Modulating NF-κB and Nrf2.
Arafa MH; Atteia HH
Neurotox Res; 2020 Feb; 37(2):380-396. PubMed ID: 31410684
[TBL] [Abstract][Full Text] [Related]
17. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L
Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Cisplatin-Induced Ototoxicity and Prevention.
Rybak LP; Mukherjea D; Ramkumar V
Semin Hear; 2019 May; 40(2):197-204. PubMed ID: 31036996
[TBL] [Abstract][Full Text] [Related]
19. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
Smith EML; Knoerl R; Yang JJ; Kanzawa-Lee G; Lee D; Bridges CM
Cancer Control; 2018; 25(1):1073274818756608. PubMed ID: 29480026
[TBL] [Abstract][Full Text] [Related]
20. Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
Hazlitt RA; Min J; Zuo J
J Med Chem; 2018 Jul; 61(13):5512-5524. PubMed ID: 29361217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
